Related Experiment Videos

Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from

John Vissing1, Geoffroy Coteur2,3, Ibrahim Turkoz4

  • 1Department of Neurology, University of Copenhagen, Copenhagen, Denmark.

Journal of Medical Economics
|July 20, 2026
PubMed

Insights

Nipocalimab significantly reduced healthcare resource utilization and costs in generalized myasthenia gravis (gMG) patients by lowering hospital admissions and emergency department visits. Worsening MG-ADL scores and high QMG respiratory scores predicted high-cost events.

Area of Science:

  • Neurology
  • Immunology
  • Health Economics

Background:

  • Generalized myasthenia gravis (gMG) is a rare autoimmune disorder with significant healthcare resource utilization (HRU) and economic burden.
  • Understanding HRU, costs, and predictors of high-cost events is crucial for managing gMG patients.

Purpose of the Study:

  • To evaluate HRU, costs, and predictors of high-cost events in adults with gMG using data from the VIVACITY-MG3 study.
  • To assess the impact of nipocalimab on HRU and associated costs in gMG patients.

Main Methods:

  • Post-hoc analysis of the VIVACITY-MG3 randomized controlled trial in seropositive gMG patients.
  • HRU endpoints included hospital admissions (HA), emergency department visits (EDV), and hospital days.
  • Logistic regression identified predictors of HA/EDV; costs were estimated using US data adjusted to 2024 USD.

Main Results:

  • Nipocalimab numerically reduced all-cause and gMG-related HA/EDV events and hospital stay duration.
  • Nipocalimab significantly reduced hospital days by 60% (all-cause) and 68% (gMG-related) PPPY, with cost offsets of $10,860-$13,253 PPPY.
  • Worsening MG-ADL and high baseline QMG respiratory scores predicted high-cost events.

Conclusions:

  • Nipocalimab significantly reduces HRU and costs in gMG patients, primarily by decreasing HA/EDV events and hospital days.
  • Clinical deterioration and high baseline disease severity are independent predictors of high healthcare costs in gMG.
Abstract

Keywords:
Generalized myasthenia graviseconomic burdenhospital resource utilizationnipocalimabpost-hoc analysispredictors of hospitalization

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...